Campath-1H treatment of multiple sclerosis.

Abstract

Campath-1H is a humanised monoclonal antibody that targets CD52, a cell surface protein expressed on lymphocytes, monocytes and eosinophils. A single dose of Campath-1H leads to a rapid and profound lymphopenia. Campath-1H has been used in Cambridge as an experimental treatment of multiple sclerosis for more than 15 years. Here, we summarise our clinical and laboratory findings, describing how this prototypical 'bench to bedside' therapy continues to inform basic science, revealing aspects of the pathogenesis of multiple sclerosis and autoimmunity.

Statistics

0501002008200920102011201220132014201520162017
Citations per Year

213 Citations

Semantic Scholar estimates that this publication has 213 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Jones2008Campath1HTO, title={Campath-1H treatment of multiple sclerosis.}, author={Joanne L. Jones and Alasdair John Coles}, journal={Neuro-degenerative diseases}, year={2008}, volume={5 1}, pages={27-31} }